THERAPEUTIC TARGETS FOR LIN-28-EXPRESSING CANCERS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 28, 2019
app pub date -
Mar 1, 2017
filing date -
Mar 1, 2017
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure identifies RNAs (including mRNAs and miRNAs) that are bound by LIN-28 in C. elegans. Many of these RNAs have clear human orthologs, and many of these human orthologs are common druggable targets in cancer and/or other diseases, such as kinases, phosphatases, methyltransferases, phosphodiesterases, etc. Accordingly, the present disclosure provides biological targets for LIN-28 expressing cancers, and which are thus useful for selecting chemical and/or biological agents for cancer treatment.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully